CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing conditionally activated biologics through its proprietary PROBODY technology platform, which masks therapeutic agents until they encounter tumor-associated proteases for selective activation in the tumor microenvironment.

The company’s lead programs include varsetatug masetecan (Varseta-M), an antibody-drug conjugate targeting epithelial cell adhesion molecule for colorectal cancer, and CX-801, a masked interferon‑alpha‑2b being evaluated in melanoma, both of which are currently in Phase 1 clinical trials.

CytomX Therapeutics, Inc. generates revenue primarily from collaboration agreements that provide upfront payments, research funding, milestone payments, and potential royalties, as it has not yet commercialized any therapeutic product.

Notable collaborations include an agreement with Amgen that delivered an upfront payment of $40.0 million and potential milestones of up to $203.0 million, a partnership with Astellas that provided an $80.0 million upfront payment and possible milestones of approximately $1.2 billion, a deal with Bristol Myers Squibb that included an upfront payment of $200.0 million under an amended agreement, a collaboration with Moderna that supplied a $35.0 million upfront payment and eligibility for milestones of up to $1.2 billion, and an arrangement with Regeneron that contributed a $30.0 million upfront payment and potential milestones of up to $0.8 billion.

The company operates through a single reportable segment.

• Reportable Segment: CytomX Therapeutics, Inc. engages in the discovery, development, and potential commercialization of conditionally activated antibody-drug conjugates such as Varseta‑M, which carries a topoisomerase‑1 inhibitor payload designed for bystander killing of tumor cells; cytokine‑based therapeutics like CX‑801, a dual‑masked interferon‑alpha‑2b intended to activate anti‑tumor immunity while limiting systemic toxicity; T‑cell engagers pursued with partners including Amgen, Astellas, Bristol Myers Squibb, and Regeneron, which redirect T cells to tumor antigens; and mRNA‑encoded masked biologics under its collaboration with Moderna, which aim to deliver PROBODY‑modified therapeutic proteins via lipid nanoparticles, all designed to improve the therapeutic index of oncology treatments by exploiting tumor‑specific protease activity.

Within the biopharmaceutical industry, CytomX Therapeutics, Inc. competes with established players such as Amgen, Bristol Myers Squibb, Roche, Merck, and Pfizer that are advancing antibody‑drug conjugates, T‑cell engagers, and cytokine‑based immunotherapies, while its differentiated PROBODY platform offers a mechanism to reduce systemic toxicity and enhance tumor selectivity, supported by a robust intellectual property portfolio of at least 245 granted patents and over 300 pending patent applications as of January 2026.

The company’s competitive advantages include its deep expertise in tumor protease biology, a versatile platform applicable to multiple modalities, and a series of strategic alliances that provide non‑dilutive funding and access to complementary technologies, enabling it to advance a broad pipeline of masked biologics without bearing the full cost of development alone.

The company's customer base consists of biopharmaceutical partners including Amgen, Astellas Pharma, Bristol Myers Squibb, Moderna, and Regeneron, with the long‑term objective of serving patients diagnosed with colorectal cancer, melanoma, and other solid tumors once its product candidates progress through clinical development and receive regulatory approval.